文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

过氧化物酶体增殖物激活受体-α在肾损伤中的作用:机制与治疗意义

[Peroxisome proliferator activated receptor-α in renal injury: mechanisms and therapeutic implications].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论综述阐明PPAR-α通过调控代谢、抗氧化、抗炎、抗纤维化和抗铁死亡参与多种肾损伤,是潜在新型治疗靶点。

本文为综述,简述PPAR-α的结构、功能与活性调节机制,系统阐述其在肾缺血/再灌注损伤、药物性急性肾损伤、脓毒症相关急性肾损伤、肾小球肾炎、糖尿病肾病、高血压肾病等肾损伤病理过程中的分子调控网络,并总结其调控代谢、抗氧化、抗炎、抗纤维化及抗铁死亡的相关机制,评价其作为新型治疗靶点的医学价值,旨在为基于PPAR-α靶向干预的肾脏保护策略提供理论依据。

要点

  • PPAR-α在肝脏、肾脏、心肌和骨骼肌等多种组织显著表达,通过调控能量稳态、氧化还原平衡、炎症反应和铁死亡等关键生理过程在多种疾病发生中起核心作用。
  • 肾损伤病因复杂多样,急性损伤因素包括缺血/再灌注、肾毒性药物、脓毒症休克和免疫性肾小球病,慢性进展性病因包括代谢病相关肾病和高血压肾病。
  • 综述系统阐明PPAR-α在急性肾损伤(肾缺血/再灌注损伤、药物性急性肾损伤、脓毒症相关急性肾损伤、肾小球肾炎)和慢性肾脏病(糖尿病肾病、高血压肾病)中的分子调控网络。
  • PPAR-α调控肾损伤的相关机制包括调节代谢、抗氧化、抗炎、抗纤维化和抗铁死亡。
  • 综述评价PPAR-α作为新型治疗靶点的医学价值,旨在为基于PPAR-α靶向干预的肾脏保护策略开发提供理论依据。

适用人群与场景

  • 肾损伤病因复杂多样,急性损伤因素包括缺血/再灌注、肾毒性药物、脓毒症休克和免疫性肾小球病;慢性进展性病因包括代谢病相关肾病和高血压肾病;危险因素包括酒精滥用、肥胖和衰老。

研究设计与关键结果

  • 本文为综述,简述PPAR-α的结构、功能与活性调节机制,系统阐述其在肾缺血/再灌注损伤、药物性急性肾损伤、脓毒症相关急性肾损伤、肾小球肾炎、糖尿病肾病、高血压肾病等肾损伤病理过程中的分子调控网络。
  • 综述总结PPAR-α调控肾损伤的相关机制,包括调节代谢、抗氧化、抗炎、抗纤维化和抗铁死亡。
  • 综述评价PPAR-α作为新型治疗靶点的医学价值,旨在为基于PPAR-α靶向干预的肾脏保护策略开发提供理论依据。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Peroxisome proliferator activated receptor-α (PPAR-α) is significantly expressed in various tissues such as the liver, kidney, myocardium, and skeletal muscle, which plays a central role in the development of various diseases by regulating key physiological processes such as energy homeostasis, redox balance, inflammatory response, and ferroptosis. As an important metabolic and excretory organ of the body, renal dysfunction can lead to water and electrolyte imbalance, toxin accumulation, and multiple system complications. The causes of kidney injury are complex and diverse, including acute injury factors (such as ischemia/reperfusion, nephrotoxic drugs, septic shock, and immune glomerulopathy), as well as chronic progressive causes [such as metabolic disease-related nephropathy, hypertensive nephropathy (HN)], and risk factors such as alcohol abuse, obesity, and aging. This review briefly describes the structure, function, and activity regulation mechanism of PPAR-α, systematically elucidates the molecular regulatory network of PPAR-α in the pathological process of kidney injury including acute kidney injury (AKI) such as renal ischemia/reperfusion injury (IRI), drug-induced AKI, sepsis-associated acute kidney injury (SA-AKI), glomerulonephritis, chronic kidney disease (CKD) such as diabetic nephropathy (DN), HN, and other kidney injury, and summarizes the mechanisms related to PPAR-α regulation of kidney injury, including regulation of metabolism, antioxidation, anti-inflammation, anti-fibrosis, and anti-ferroptosis. This review also evaluates PPAR-α's medical value as a novel therapeutic target, and aims to provide theoretical basis for the development of kidney protection strategies based on PPAR-α targeted intervention.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhou J, Luo L, Zhu J, et al. [Peroxisome proliferator activated receptor-α in renal injury: mechanisms and therapeutic implications]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41017187. doi:10.3760/cma.j.cn121430-20250318-00270

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。